

HYPERTENSION

BACKGROUND

Hypertension is one of the most common diseases in this country. It is a major contributor to cardiovascular complications and death. The Eighth Joint National Committee (JNC 8) used evidence-based methods, developing Evidence Statements and recommendations for blood pressure (BP) treatment based on a systematic review of the literature in order to establish recommendations for clinicians, especially primary care clinicians.

Compared to JNC 7, JNC 8 raised the systolic treatment initiation threshold at age 60 from 140 to 150 mm Hg. In general the treatment threshold for diabetics is 140/90, not the lower 130/80 as in JNC 7. JNC 8 has broadened treatment options to four classes for nonblack patients and two classes for black patients. β -blockers are no longer recommended for initial therapy because they might afford less protection against stroke.

DIAGNOSIS

JNC 8 guidelines, define thresholds for pharmacological treatment, whereas the JNC 7 guidelines focused on the definitions of hypertension and pre-hypertension.¹

TREATMENT & GOALS

Adapted from JNC 8¹

Population Based Recommendations	Population & Initiation of Pharmacologic Treatment	Additional Comments The letters A, B, C, or E following each recommendation represent the evidence level that supports each recommendation. Evidence level A is the strongest, ranging to E which is consensus based evidence.
Recommendation 1 General population aged ≥60 years	Initiate treatment to lower blood pressure (BP) at systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. Goal is SBP <150 mm Hg and DBP <90 mm Hg. (Strong Recommendation – Grade A	General population aged ≥60 years, if pharmacologic treatment results in lower SBP (e.g., <140 mm Hg) and treatment is well tolerated, without adverse effects on health or quality of life, treatment does not need to be adjusted. Expert Opinion – Grade E
Recommendation 2 General population <60 years	Initiate treatment to lower BP at DBP ≥90 mm Hg. Goal is DBP <90 mm Hg.	For ages 30-59 years, Strong Recommendation – Grade A; For ages 18- 29 years, Expert Opinion – Grade E
Recommendation 3 General population <60 years	Initiate treatment to lower BP at SBP ≥140 mm Hg. Goal is SBP <140 mm Hg.	Expert Opinion – Grade E
Recommendation 4 Population aged ≥18 years with chronic kidney disease (CKD)	Initiate treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal is SBP <140 mm Hg and goal DBP <90 mm Hg.	Expert Opinion – Grade E
Recommendation 5 Population aged ≥18 years with diabetes	Initiate treatment to lower BP at SBP ≥140 mm Hg or DBP ≥90 mm Hg. Goal SBP 120-125 mm Hg (automated) or 125-130 mm Hg (manual).	Expert Opinion – Grade E



CLINICAL PRACTICE GUIDELINE ADULT MEDICINE

Population Based	Population & Initiation of Pharmacologic	Additional Comments
Recommendations	Treatment	The letters A, B, C, or E following each
		recommendation represent the evidence
		level that supports each recommendation.
		Evidence level A is the strongest, ranging to
		E which is consensus based evidence.
Recommendation 6	Initial antihypertensive treatment should include a	Moderate Recommendation – Grade B
Nonblack population,	thiazide-type diuretic, calcium channel blocker	
including those with	(CCB), angiotensin-converting enzyme inhibitor	
diabetes	(ACEI), or angiotensin receptor blocker (ARB).	
Recommendation 7	Initial antihypertensive treatment should include a	For general black population: Moderate
Black population,	thiazide-type diuretic or CCB.	Recommendation – Grade B; for black
including those with		patients with diabetes: Weak
diabetes		Recommendation – Grade C
Recommendation 8	Initial (or add-on) antihypertensive treatment	Moderate Recommendation – Grade B
Population aged ≥18	should include an ACEI or ARB to improve kidney	
years with CKD	outcomes. This applies to all CKD patients with	
Recommendation 9	hypertension regardless of race or diabetes status.	Funart Oninian Crada F
Recommendation 9	The main objective of hypertension treatment is to	Expert Opinion – Grade E
	attain and maintain goal BP. If goal BP is not	
	reached within a month of treatment, increase the	
	dose of the initial drug or add a second drug. The	
	clinician should continue to assess BP and adjust	
	the treatment regimen until goal BP is reached. If	
	goal BP cannot be reached with 2 drugs, add and	
	titrate a third drug. Do not use an ACEI and an ARB	
	together in the same patient. If goal BP cannot be	
	reached using only the recommended categories	
	because of a contraindication or the need to use	
	more than 3 drugs to reach goal BP,	
	antihypertensive drugs from other classes can be	
	used. Referral to a hypertension specialist may be	
	indicated for patients in whom goal BP cannot be	
	attained using the above strategy or for the	
	management of complicated patients for whom	
	additional clinical consultation is needed.	



RECOMMENDATIONS

- Patient age >= 60 years achieve and maintain BP < 150/90; a goal of <140/90 mmHg may be appropriate for some patients. The choice between these goals depends on patient-specific factors like overall health, comorbid conditions, postural blood pressure changes, number of medications needed and individual values
- Patient age < 60 years achieve and maintain BP < 140/90
- Adjust SBP goal if patient has concurrent condition(s), such as diabetes and/or chronic kidney disease
- Amida Care supports the use of home blood pressure monitoring, consider its role in management

SOURCES

- JAMA Editorial: "Updated Guidelines for Management of High Blood Pressure: Recommendations, Review, and Responsibility"(jama.jamanetwork.com) (Dec. 18, 2013) <u>http://www.aafp.org/news/health-of-the-public/20131218hypertensiongdln.html</u>
- UpToDate: <u>http://www.uptodate.com/contents/overview-of-hypertension-in-adults?source=search_result&search=hypertension+adult&selectedTitle=1~150</u> (literature current through Nov.2016) Sources accessed 12/16/2016
- Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435. <u>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00805-3/ppt</u>
- 4. Aksnes TA¹, Skårn SN, Kjeldsen SE. Treatment of hypertension in diabetes: what is the best therapeutic option. <u>Expert Rev Cardiovasc Ther.</u> 2012 Jun;10(6):727-34
- 5. Peterson ED, Gaziano JM, Greenland P. Recommendations for Treating Hypertension: What are the Right Goals and Purposes? <u>http://jamanetwork.com/journals/jama/fullarticle/1791422</u>
- American Academy of Family Physicians (AAFP). <u>Hypertension Clinical Practice Guideline</u> All of the above sources were accessed on 12/15/2016.